

Investigator Perspectives on Available Research and Challenging Questions
in Renal Cell Carcinoma: A Post-ASCO Annual Review

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase III TIVO-3 trial demonstrated which of the following outcomes for patients with previously treated advanced renal cell carcinoma (RCC)?**
 - An overall survival benefit with tivozanib compared to sorafenib
 - A progression-free survival (PFS) benefit with tivozanib compared to sorafenib**
 - A progression-free survival benefit with sorafenib compared to tivozanib
 - None of the above
- 2. The Phase II KEYNOTE-B61 trial demonstrated durable responses with lenvatinib/pembrolizumab for patients with which of the following histologic subtypes of non-clear cell RCC (nccRCC)?**
 - Papillary
 - Chromophobe
 - Translocation
 - Durable responses were observed across all histologic subtypes**
- 3. Which of the following adverse events was most commonly observed among patients receiving belzutifan for von Hippel-Lindau-associated RCC in the Phase II LITESPARK-004 trial?**
 - Hypertension
 - Delay in wound healing
 - Anemia**
 - GFR (glomerular filtration rate) decrease
- 4. The Phase II FORTUNE trial is evaluating the combination of tivozanib and nivolumab in which of the following settings?**
 - Adjuvant therapy for clear cell RCC (ccRCC)
 - Adjuvant therapy for nccRCC
 - Advanced ccRCC
 - Advanced nccRCC**
- 5. The Phase III KEYNOTE-564 trial revealed an improvement in which of the following outcomes with adjuvant pembrolizumab for patients with ccRCC and an increased risk of recurrence after surgery?**
 - Disease-free survival
 - Overall survival
 - Both a and b**
 - Neither a nor b